OrbiMed’s Sight Sciences SGHT Stock Holding History

OrbiMed’s Portfolio SGHT Stock Details SGHT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-200,000	Closed	-$1.8K	–	144
2022 Q2	$1.8K	Hold	200,000	–	–	0.03%	134
2022 Q1	$2.31M	Hold	200,000	–	–	0.04%	131
2021 Q4	$3.51M	Hold	200,000	–	–	0.05%	143
2021 Q3	$4.54M	Buy	+200,000	New	+$6.57M	0.05%	154

Other funds holding SGHT

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OrbiMed's SGHT Position: Q3 2022 in Review

OrbiMed sold out of Sight Sciences (SGHT) in Q3 2022, closing a stake of 200,000 shares — an estimated $1.8K sold.

OrbiMed first reported a position in SGHT in Q3 2021 and held it in 4 quarters. The position peaked at $4.54M in Q3 2021. 68 funds tracked by Wall St. Rank hold SGHT as of Q3 2022.

OrbiMed reported no remaining Sight Sciences position as of Q3 2022 after selling out during the quarter.
OrbiMed sold 200,000 Sight Sciences shares in Q3 2022, an estimated $1.8K.
OrbiMed first reported a position in Sight Sciences in Q3 2021 and held it in 4 quarters.
OrbiMed's Sight Sciences position peaked at $4.54M in Q3 2021.
68 funds tracked by Wall St. Rank held Sight Sciences as of Q3 2022.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.